Congo health minister's resignation over Ebola snub could unblock new vaccine
Congo's health minister resigned on Monday after being stripped of responsibility for managing the country's Ebola outbreak, potentially paving the way for the introduction of a second vaccine to contain the spreading epidemic. Oly Ilunga has overseen Congo's near year-long response to what is the ...
A growing measles outbreak in the Philippines killed at least 25 people last month, officials said Thursday, putting some of the blame on mistrust stoked by a scare over an anti-dengue fever vaccine. Most of the dead are children and the toll is expected to ...
Takeda dengue vaccine meets main goal of trial; detailed results to come
Takeda Pharmaceutical Co. said Tuesday that its experimental dengue vaccine appears to be safe and effective at preventing all four types of the mosquito-borne disease, meeting the main goal of the drugmaker's late-stage clinical trial. The company said no significant safety concerns have emerged to ...
U.S. agency helps fund Takeda effort to develop Zika vaccine
Japanese drugmaker Takeda Pharmaceutical Co. on Thursday said it is developing a vaccine to prevent the Zika virus, which has been linked to severe birth defects, and has secured funding from a U.S. government agency. Takeda, which is also working on vaccines for other mosquito-borne ...
Zika funds near end, vacationing Congress told as virus spreads in Florida, hits 33 service members
The Obama administration warned Congress Wednesday that money to fight the Zika virus is on the verge of running out amid political stalemate on Capitol Hill. In a letter to key lawmakers, the secretary of Health and Human Services said the National Institutes of Health ...
Trial vaccine offers quick-response promise for flu, Ebola, Zika, works with mice
A type of experimental vaccine that can be made in just a week and has protected mice against influenza, Ebola and Zika viruses may offer promise for quick responses to disease outbreaks in people, according to Massachusetts Institute of Technology researchers. MIT scientists said their ...
Cervical cancer vaccine suit filed over side effects
Sixty-three women and girls who reported side effects from cervical cancer vaccines sued the government and drugmakers on Wednesday as a sharp divide remained over the risks the medicine poses. The plaintiffs, ranging in age from 15 to 22, filed suits in district courts in ...
U.S. Army, France's Sanofi to speed effort to develop Zika vaccine
French drugmaker Sanofi said on Wednesday it had struck a research and development deal with the U.S. Army to speed up the development of a vaccine against the mosquito-borne Zika virus. Sanofi is the only major drugmaker working on a vaccine against Zika, which has ...
Victims of government-recommended cervical cancer vaccine to sue state, drugmakers
Victims suffering side effects from cervical cancer vaccines that were once recommended by the government announced Wednesday they will file a lawsuit against the state and drugmakers. "Many victims are still suffering from side effects of the human papillomavirus (HPV) vaccines Cervarix and Gardsil, which ...
Zika poses Asia, Oceania, South Europe threat; Sanofi joins race for viable vaccine
The Zika virus could spread to Africa, Asia and Southern Europe, the World Health Organization said on Tuesday, as major French drugmaker Sanofi SA and others joined the race to create a vaccine. A day after Geneva-based WHO declared an international public health emergency due ...
Mexico approves world's first dengue vaccine after 20 years of research
The first vaccine against dengue fever won clearance in Mexico, an initial step toward preventing a mosquito-borne infection that puts half of the world's population at risk. Sanofi expects more approvals in "upcoming weeks" for the product, called Dengvaxia, in Latin America and Asia, Olivier ...
Novavax says vaccine proving effective against RSV in early studies with seniors
Early research in older adults found an experimental vaccine prevented nearly two-thirds of serious cases of a common, seasonal respiratory virus that annually kills thousands of vulnerable people — babies and senior citizens. If further testing by vaccine developer Novavax Inc. goes well, in a ...
